Around half a million men who have sex with men in the EU need PrEP but cannot access it

October 11, 2019

This estimate on the "PrEP gap" in Europe was published in a paper in Eurosurveillance today stating that 500 000 men who have sex with men in the European Union currently cannot access HIV pre-exposure prophylaxis (PrEP), despite being very likely to use it. The paper is based on findings from European Centre for Disease Prevention and Control monitoring and the European Men-Who-Have-Sex-With-Men Internet Study (EMIS-2017).

Sex between men remains the predominant mode of HIV transmission in the countries of the European Union and European Economic Area (EU/EEA), accounting for 38% of all new HIV diagnoses in 2017. HIV pre-exposure prophylaxis (PrEP) is the use of antiretroviral medicines to prevent HIV infection among people who are HIV-negative, and its efficacy is well-documented.

Creating a gap: no easy access to free or subsidised PrEP

To identify the level of unmet need for PrEP, the authors from the National AIDS Trust (NAT), the London School of Hygiene and Tropical Medicine, Public Health England and ECDC used data from EMIS-2017 to compare the proportion of men who have sex with men (MSM) who stated they were 'very likely' to use PrEP if it were accessible to them with the proportion of those who currently use PrEP from any available source. The estimated 'PrEP gap' ranged from 44.8% in Russia to 4.3% in Portugal. An overall estimate of the PrEP gap for the EU was calculated as 17.4%, equating to 500,000 (95% CI: 420,000-610,000) MSM who would be very likely to use PrEP but are not currently able to access it.

Lead author Rosalie Hayes, Senior Policy & Campaigns Officer at NAT, said: "These findings should act as a wake-up call to countries across the EU. Although progress has been made in making reimbursed PrEP nationally available, our estimate that around half a million men who have sex with men are still unable to access PrEP despite being very likely to use it is very concerning. The longer the delay in access to PrEP for these men, the more HIV infections will occur."

The authors highlight that they could only estimate the PrEP gap for MSM because there is no equivalent data source to EMIS-2017 for other key populations in need of PrEP. They recommend that national health authorities should focus on improving accessibility of PrEP to women and heterosexual men at high risk of HIV, as well as an expansion of PrEP availability more generally.

"ECDC has been advocating since 2015 that EU Members States should give consideration to integrating PrEP into their existing HIV prevention package for those most at-risk of HIV infection, starting with men who have sex with men", stresses Andrew Amato Gauci, Head of the ECDC programme on HIV/AIDS, STI and viral hepatitis.

Despite this recommendation, national provision of PrEP remains limited. ECDC's annual survey on the progress of the implementation of the Dublin Declaration on Partnership to Fight HIV/AIDS found that in 2019, only 14 out of 53 responding countries in Europe and Central Asia provided reimbursed PrEP via their national health service while 10 countries reported that PrEP was available but not fully reimbursed. Among the countries where PrEP is not accessible nationwide and reimbursed, respondents to the survey most commonly named the cost of implementing PrEP as the main barrier.

How does PrEP work?

Pre-exposure prophylaxis is a drug taken by HIV-negative people before sex that reduces the risk of getting HIV. When taken as prescribed, it is nearly 100% effective in preventing HIV infection. As an additional prevention option, PrEP has the potential to help reverse the increase in new HIV infections in Europe.

European Centre for Disease Prevention and Control (ECDC)

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to